A medical oncologist at a specialty cancer center discusses their current experiences with using monitoring and MRD tests for their patients. This medical oncologist is most familiar with ctDNA monitoring in NSCLC and CRC patients, as well as some patients with renal or bladder cancer. They expect their use of these technologies to increase in coming years, as they see utility in other cancer types such as breast and even pancreatic. Their current test of choice is Signatera, though they were once a Guardant user, having since found preferences for tumor-informed testing. They expect that increased payer coverage and stronger clinical utility data will expedite test implementation, as they themselves would double their test volumes if prices allowed for it.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care